Insulin to cost $30 as California secures contract to combat diabetes: Newsom

California will cut patients’ cost for insulin by 90% to $30, regardless of their insurance plan, Gov. Gavin Newsom announced Saturday.

The state has a contract with non-profit generic-drug company Civica to manufacture insulin, a hormone used for treating diabetes.

When the new, cheaper drug will become available is not clear: Civica and the state Health and Human Services Agency are working to identify a manufacturing facility in California, according to the governor’s announcement.

Patients who pay cash for insulin will save $2,000 and $4,000 a year, Newsom’s office said, citing “egregious cost-shifting that happens in traditional pharmaceutical price games.”

More than three million Californians have diabetes, according to the American Diabetes Association. Diabetics have medicals costs about 2.3 times higher than people without the disease, the group said.

A 10-milliliter vial of insulin usually costs $300, according to the announcement. A box of five pre-filled 3-milliliter insulin pens will cost no more than $55, compared to the typical $500-plus, the governor’s office said.

“People should not be forced to go into debt to get life saving prescriptions,” Newsom said. “Californians will have access to some of the most inexpensive insulin available, helping them save thousands each year.”

No new prescriptions will be required, and California residents will be able to ask for the generic insulin at participating brick-and-mortar and online pharmacies.

The state plans to make available insulins biologically similar to the glargine, aspart and lispro versions of the drug. The glargine-type drug is expected to be interchangeable with Lantus-brand insulin, the aspart-type drug interchangeable with Humalog, and the lispro-type interchangeable with Novolog.

Meanwhile, drug maker Eli Lilly said earlier this month it had slashed the cost of its most commonly used insulin by 70% and capped out-of-pocket insulin costs at $35 for people with private health insurance using participating pharmacies.

Source link

Denial of responsibility! insideheadline is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave A Reply

Your email address will not be published.